Hemostasis Fellowship Program

The Hemostasis Fellowship Program, a fellowship in Congenital and Acquired Bleeding Disorders, was established in the fall of 2001 as a result of a collaborative effort between Novo Nordisk Canada Inc., the Canadian Hemophilia Society and the Association of Hemophilia Clinic Directors of Canada. We are happy to confirm that for 2010, the  Fellowship will continue to be made possible thanks to the generous financial support of CSL Behring Canada. As a global leader in the plasma protein biotherapeutics industry, CSL Behring researches, develops, manufactures and markets biotherapies used to treat serious diseases. Their five core company values underscore their commitment to providing the best possible therapies and services: customer focus; innovation; integrity; collaboration; and superior performance. CSL Behring Canada is proud of its heritage that has delivered biotherapies for life for more than a century. They are committed to providing safe and effective biotherapies to Canadians, now and in the future. The AHCDC and the CHS are proud to be in a partnership with CSL Behring in order to offer this important Fellowship Program.

The goal of this ongoing annual research program that encompasses a one-year fellowship appointment, valued at $75,000 , is to provide fellows in hematology or other relevant fields the opportunity to acquire clinical or research skills necessary to improve the care, treatment and quality of the lives of patients with hemophilia and other congenital or acquired bleeding disorders.